Application No. 10/796,522 Response Dated Reply to Office Action of January 28, 2009

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the aboveidentified application.

Claims:

1. - 73. (Cancelled)

74. (Cancelled) A therapeutic composition comprising an amyloid-beta (Aβ) polypeptide linked to a therapeutic non-Aβ polypeptide, and a sterile pharmaceutically acceptable carrier or excipient,

wherein said therapeutic non-Aβ polypeptide improves or stabilizes one or more clinical features of a CNS disorder in a patient,

wherein the clinical features of a CNS disorder are selected from the group consisting of cognitive function, memory, behavior, language skills, motor skills and patient rigidity,

wherein the non-A β polypeptide is an antibody,

and wherein the antibody is polyamine modified.

75. (Currently Amended) The composition of claim [[74]]76, wherein the antibody is a monoclonal polyamine modified antibody.

76. (Currently Amended) A therapeutic composition comprising an amyloid-beta (Aβ) polypeptide linked to an anti- Aβ antibody, and a sterile pharmaceutically acceptable carrier or excipient,

The composition of claim 75 wherein the <u>antibody is monoclonal</u> polyamine modified <u>and antibody</u> has specific binding affinity for amyloid <u>peptide</u> comprising residues 1-39 of SEQ ID NO:1[[.]],

wherein the anti- Aβ antibody improves or stabilizes one or more clinical features of a CNS disorder in a patient,

wherein the clinical features of a CNS disorder are selected from the group consisting of congnitive function, memory, behavior, language skills, motor skills and patient rigidity.

QB\7441440.1 2

Application No. 10/796,522 Response Dated Reply to Office Action of January 28, 2009

- 77. (Currently Amended) The composition of claim [[74]]76, wherein the non-amyloid-beta (Λβ) polypeptide polyamine modified anti- Λβ antibody is a humanized antibody.
- 78. (New) The composition of claim 76, wherein the polyamine modified anti-Aβ antibody comprises a Fab fragment.
- 79. (New) The composition of claim 76, wherein the polyamine modified anti-Aβ antibody comprises a single chain Fv antibody fragment.
- 80. (New) The composition of claim 76, wherein the polyamine modified anti-Aβ antibody is labeled with a radioisotope or a contrast agent.
- 81. (New) The composition of claim 76, wherein the polyamine modified anti-A β antibody is labeled with a contrast agent.

QB\7441440.1 3